Chimerix, Inc. to Present at Two Upcoming Healthcare Conferences in November

The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

http://www.biospace.com/news_story.aspx?StoryID=279480&full=1